Enovis Co. (NYSE:ENOV) Shares Purchased by First Trust Advisors LP

First Trust Advisors LP grew its holdings in Enovis Co. (NYSE:ENOV - Free Report) by 11.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 402,483 shares of the company's stock after acquiring an additional 42,216 shares during the period. First Trust Advisors LP owned about 0.71% of Enovis worth $17,661,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Aster Capital Management DIFC Ltd acquired a new stake in Enovis in the 4th quarter valued at about $29,000. Quadrant Capital Group LLC grew its holdings in Enovis by 53.0% during the 4th quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after acquiring an additional 239 shares in the last quarter. UMB Bank n.a. increased its position in shares of Enovis by 128.2% in the 4th quarter. UMB Bank n.a. now owns 778 shares of the company's stock valued at $34,000 after purchasing an additional 437 shares during the last quarter. Pinnacle Bancorp Inc. raised its holdings in shares of Enovis by 54.5% in the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock valued at $37,000 after purchasing an additional 300 shares in the last quarter. Finally, Sterling Capital Management LLC lifted its position in shares of Enovis by 56.2% during the 4th quarter. Sterling Capital Management LLC now owns 3,259 shares of the company's stock worth $143,000 after purchasing an additional 1,173 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company's stock.

Analyst Ratings Changes

Separately, Needham & Company LLC restated a "buy" rating and issued a $64.00 price target on shares of Enovis in a research note on Wednesday, April 9th.

Enovis Stock Up 2.1 %

NYSE:ENOV traded up $0.74 during midday trading on Friday, hitting $35.34. 196,639 shares of the company were exchanged, compared to its average volume of 985,158. Enovis Co. has a fifty-two week low of $29.32 and a fifty-two week high of $53.84. The company has a market capitalization of $2.02 billion, a PE ratio of -16.13 and a beta of 1.86. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. The company has a fifty day simple moving average of $35.79 and a 200 day simple moving average of $41.82.

Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.06. The firm had revenue of $560.98 million during the quarter, compared to analysts' expectations of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. As a group, equities analysts anticipate that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.